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Abstract
Both Dengue (DENV) and Chikungunya (CHIKV) viruses can be transmitted by Aedes
mosquito species and the diseases that they cause have several clinical symptoms in com‐
mon. Co-circulation of DENV and CHIKV is increasing around the world and must
therefore be considered as an emerging threat with an important public health concern.
At present, very little is known about the clinical manifestations and biological conse‐
quences of coinfection by both viruses. Thus, numerous questions such as clinical severi‐
ty and dynamics of viral replication of DENV and CHIKV coinfections, as well as
vectorial competence, have yet to be addressed in this important and challenging re‐
search area. The ensuring knowledge will enhance the clinical surveillance and the devel‐
opment of diagnostic tools able to differentiate DENV and CHIKV in order to early detect
virus invasion and local transmission, as well as to improve patient care and timely con‐
trol measures. In this review, we highlight the current knowledge on DENV and CHIKV
coinfections. We also discuss research perspectives and challenges in order to further un‐
derstand the ecology and biology of this phenomenon.
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1. Introduction
Arthropod-borne viruses represent a global threat for public health as they can be transmitted
to humans by hematophagous arthropods that are rapidly spreading worldwide. These
viruses belong to four major families, Flaviviridae, Togaviridae, Rhabdoviridae, Reoviridae, and
Bunyaviridae, and are the etiologic agents of severe pathologies, such as yellow fever, dengue,
and chikungunya diseases.
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Dengue virus (DENV) is perhaps the most relevant arbovirus in terms of morbidity, mortality,
and socioeconomic impact, threatening more than 2.5 billion individuals worldwide [1]. It
belongs to the Flaviviridae family, genus Flavivirus, and is composed by four closely related
serotypes (DENV-1, -2, -3, -4), all of which share the same icosahedral and enveloped structure
with an average diameter of 50 nm. Its genome is composed of a single-stranded positive sense
RNA molecule of approximately 11 kb that codifies three structural (Capsid, Membrane, and
Envelope) and seven nonstructural proteins (NS1/NS2A/NS2B/NS3/NS4A/NS4B/NS5),
flanked by two untranslated regions (UTRs) [2]. DENV is transmitted to humans by blood-
feeding females of Aedes mosquitoes and, although the large majority of infections remain
asymptomatic, some of them can cause a spectrum of illnesses, ranging from a flu-like disease
of mild severity known as dengue fever (DF), to more severe clinical manifestations such as
dengue hemorrhagic fever (DHF) that can progress to dengue shock syndrome (DSS) and
death [3, 4].
Chikungunya virus (CHIKV), on the other hand, belongs to the Togaviridae family, genus
Alphavirus. Like DENV, it is a small icosahedral-shaped enveloped virus approximately 70 nm
in diameter. Its genome is a single-stranded positive sense RNA molecule of approximately
12 kb that contains two open reading frames (ORFs): the N-terminal ORF encodes four
nonstructural proteins (nsP1 to nsP4), while its C-terminal counterpart encodes the five
structural proteins C, E1, E2, E3, and 6K [5]. CHIKV is also transmitted to humans by the bite
of Aedes mosquitoes. Clinically, infection by CHIKV is characterized by fever, headache,
fatigue, rash and intense, invalidating and often persistent arthralgia that can last for years in
30–40% of infected individuals. Although rare, neurologic complications can be observed,
particularly among infected neonates. The rate of mortality has been estimated to be 1 in 1000
[6, 7]. Since its first documented epidemic in 1952 in Africa, sporadic CHIKV outbreaks were
reported in numerous African and Asian countries, until the virus dramatically emerged
during the last decade [8]. Since then, the virus has been continuously expanding and in 2013
it reached South America and the Caribbean basin causing more than 440,000 cases of disease
in more than 20 countries by mid-2014 [9, 10].
Since Aedes mosquitoes can be vectors of both DENV and CHIKV and as the endemic areas of
these two viruses often overlap, cocirculation of DENV and CHIKV has been reported in
various geographic areas, including Southeast Asia and intertropical Africa. However, despite
increasing evidence showing that coinfection of humans by DENV and CHIKV is likely to be
an emerging trend, very little is known about the clinical manifestations and biological
consequences of this phenomenon. This represents an exciting area of research as several
scientific questions remain to be answered. Are the cases of coinfection linked to the propa‐
gation of a specific species of Aedes mosquitoes? Can these coinfections increase the incidence
of severe forms of dengue and chikungunya diseases? What are the dynamics of viral repli‐
cation when both viruses infect the same cells? What are the cellular pathways that are altered
upon coinfection and how do they contribute to the pathophysiology of the diseases? The
current chapter will try to shed light on these interrogations by reviewing all the available data
on DENV-CHIKV coinfections.
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2. Epidemiology
Although similar in some aspects, the history traits and epidemiology of DENV and CHIKV
have followed different patterns, both intrinsically linked to the ecology of the mosquito
vectors. These topics will be reviewed individually for each virus and the cases of coinfection
will be finally analyzed.
2.1. Dengue virus
2.1.1. History and epidemiology
The name dengue seems to derive from the Swahili ki-dinga pepo, which was employed to
describe a disease characterized by cramp-like seizures. The word was introduced in the
Caribbean by the slave trade from East Africa during the 1800s and progressively changed to
“dengue” [11]. Dengue-associated symptoms are almost indistinguishable from those caused
by other viral agents such as CHIKV, but it is generally assumed that the first reports of dengue-
like illness were described in China between 269 and 992 BC. The first detailed clinical
descriptions were made in the late eighteenth century by Benjamin Rush and David Bylon
after epidemic episodes in Philadelphia and Indonesia, respectively [12, 13]. These cases were
associated to flying insects developing in water reservoirs, but it was not until the beginning
of the twentieth century that Aedes mosquitoes were identified as the main transmitting vectors
of the virus [14, 15]. During World War II, increasing cases of dengue among the troops
deployed in Africa and the Pacific led to substantial efforts to isolate the virus. Not surprisingly,
the first two serotypes of DENV (DENV-1 and DENV-2) were isolated during this period in
the Pacific [16]. DENV-3 and DENV-4 were discovered in the 1950s in Southeast Asia in the
Philippines and Thailand [17].
Although  the  virus  was  initially  thought  to  have  originated  in  Africa,  serological  and
phylogenetic studies rather point toward an Asiatic origin with a subsequent propagation to
the African continent and to the Americas [18]. By analyzing the substitution rate of the
Envelope (E) gene from DENV, it has been estimated that the origin of the virus is likely to
date back to 1000 years ago and that it used primates as a reservoir [19]. The four sero‐
types of DENV seem to have evolved in the rainforests of Southeast Asia and cross-species
transmission to humans have occurred independently in all four serotypes between 125 and
320 years ago for DENV-1 and DENV-2, respectively [3, 19, 20]. According to the results from
sequence analysis of the junction of the E and NS1 genes, the DENV-1 serotype has been
further divided in five genotypes (I–V), while the same analysis of the E and M genes classifies
DENV-3 isolates into four genotypes. DENV-2 and DENV-4 are conformed by five and three
genotypes, respectively [18].
It is believed that the sylvatic forms of DENV have caused sporadic and accidental outbreaks
in humans, essentially among rural communities. The burden of dengue disease seems to be
linked to the widespread colonization of the tropics by Aedes aegypti, a species that is highly
permissive to DENV and exhibits an anthropophilic behavior, thereby mediating an efficient
interhuman transmission. Originally from West Africa, where it acquired its urban preference,
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Ae. aegypti may have been introduced in the Americas and Asia by sailing ships, creating the
ideal conditions for the spread of the disease worldwide [21]. Indeed, until the 1970s, less than
100,000 cases of dengue, diagnosed by febrile illness and hemorrhagic manifestations were
registered yearly, and DHF was documented only in a dozen of countries. Furthermore,
concomitant circulation of more than one serotype of DENV in a geographic region, known as
hyperendemicity, was restrained to Central America, Southeast Asia, and West Africa. Thirty
years later, DENV had become hyperendemic in all continents, except Antarctica, and was
responsible for more than 500,000 cases of DHF and DSS reported in almost 60 countries [22].
It has been estimated that 2.5 billion individuals are at risk of infection, especially in the
Americas and Asia. Recent investigations estimate to 390 million the number of DENV
infections per year worldwide, leading to 96 million symptomatic dengue cases [1]. Several
factors may explain the worldwide emergence of DENV. The most important one is the
demographic burden observed after World War II that led to the occupation of ecological
niches where the virus was circulating [18]. Unplanned urbanization with inadequate waste
management and water distribution systems have facilitated the development of Ae. aegypti
mosquitoes in densely populated areas. The increased circulation of people and merchandise
has also allowed the concomitant spread of both the virus and its vectors to new geographical
areas [22, 23]. Furthermore, the lack of continuity in programs aimed to eradicate the mosqui‐
toes by massive fumigation, allowed the resurgence of Aedes populations in areas that were
almost freed from them, particularly in South America [24].
2.1.2. Transmission and vector competence
Two main cycles of transmission have been described for DENV (Figure 1). The primitive
sylvatic enzootic transmission, in Asia and Africa, involves Aedes spp. as vectors and lower
primates as reservoirs. Occasionally, blood-feeding females of Aedes mosquitoes may transmit
DENV to rural human communities, but these are considered as accidental contacts [3]. The
urban cycle is the most relevant and challenging type of transmission, being responsible for
the emergence of dengue during the twentieth century. Indeed, DENV can be maintained in
a mosquito-human-mosquito cycle in urban areas, having lost the dependency on an enzootic
cycle for transmission [22]. The urban cycle involves essentially Ae. aegypti as a vector, since
this mosquito has been shown to be highly anthropophilic. This species feeds almost exclu‐
sively on human blood as a protein source for egg development [25–27]. Furthermore, Ae.
aegypti prefers to lay its eggs in artificial water containers such as used tires, cisternae and
flower pots that surround human habitats, thereby transmitting the virus transovarially to its
progeny [28, 29]. It also feeds on multiple human hosts during a single gonotrophic cycle,
resting indoors after the blood meal. This behavior ideally contributes to sustain the urban cyle
of transmission as it increases the probability of becoming infected and transmitting the virus
to multiple hosts [27].
Other species, such as Ae. polynesiensis and Ae. albopictus may also account, although as yet to
a lesser extent, for the DENV urban cycle of transmission. In that sense, an increasing attention
has been paid to the role of Ae. albopictus in the spread of DENV worldwide. This species is
currently the most invasive mosquito in the world [30] and several vector competence
experiments performed under laboratory conditions have shown that Ae. albopictus mosqui‐
toes are more susceptible to DENV than Ae. aegypti [31–34], raising concerns over the possibility
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that the expansion of this vector will increase the risk of DENV spreading to new geographical
areas. However, these experiments remain controversial, because conflicting results have been
obtained showing that Ae. aegypti is more, or equally, susceptible to DENV infection than its
counterpart Ae. albopictus [35–37]. In a very interesting paper, Lambrechts et al. [38] analyzed
the relative public health importance of Ae. albopictus for DENV transmission, by performing
a meta-analysis of reported studies that compared the oral susceptibility of Ae. aegypti and Ae.
albopictus to DENV. The results revealed that although Ae. albopictus was more susceptible to
infection than Ae. aegypti, as measured by midgut infection, the rate of virus dissemination to
other tissues, as measured by the presence of the virus in the mosquito’s head, was lower for
Ae. albopictus [38]. Thus, according to these laboratory experiments, Ae. albopictus would not a
represent a serious concern for DENV spread, as compared to Ae. aegypti, because of its lower
capacity to become infectious and to act as an efficient vector. As pointed out by the authors,
vector competence experiments are only one component of the natural and more complex
vectorial capacity of a mosquito, which depends on other factors such as the ecology, the
behavior, and the genetics of the vector and the virus. For example, it has been shown that
vector competence can vary significantly among the vector subspecies: the Ae. aegypti aegypti
subspecies, which is more anthropophilic than the Ae. aegypti formosus subspecies, is also more
susceptible to DENV infection [39]. In addition, the DENV genotype is determinant, since Ae.
aegypti is less susceptible to American DENV-2 genotypes than to Asian genotypes [40, 41].
Therefore, laboratory experiments of vector competence should be carefully interpreted and
should be validated by entomological and ecological studies in the field. In that sense, several
ecological observations indicate that the contribution of Ae. albopictus to the emergence of
DENV should not be underestimated: (i) Ae. albopcitus was responsible of DENV outbreaks in
areas where Ae. aegypti was absent or rare [26], such as Macao (China) [42] and Hawaii in 2001
[43], La Réunion Island in 2004 [44], Mauritius in 2009 [45], and Europe in 2010 when the first
autochthonous dengue cases were reported in France [46] and Croatia [47]. (ii) The vector is
massively and actively spreading worldwide and is, as mentioned above, considered to be one
of the most invasive mosquito species in the world. Since 1979 it has colonized large areas of
North, Central, and South America, Africa, Australia, and more than 20 countries in Europe
[30, 48], where it has been mainly introduced through the trade of used tires [48, 49]. (iii) In
contrast to Ae. aegypti, Ae. albopictus has the potential to adapt to low temperatures, allowing
to colonize temperate climates with cold winters such as those found in Europe and North
America. Indeed, it has been shown that immature forms of Ae. albopictus can develop in
temperatures as low as 10ºC [50], and that some populations have a diapausing egg state,
allowing them to resist cold winters with average temperatures below 0ºC [51, 52]. This
capacity to resist low and adverse temperatures is linked to an increased efficiency to synthe‐
size lipids in cold temperatures, as compared to Ae. aegypti, restricting this latter species to
tropical and subtropical areas [53, 54]. (iv) Although it has generally been assumed that the
feeding behavior of Ae. albopictus is opportunistic and zoophilic, mainly ingesting blood from
nonhuman mammals, some studies have shown that Ae. albopictus mosquitoes caught in the
wild preferentially feed on humans in Cameroon [55], Thailand [25], North Carolina [56], and
the Andaman and Nicobar archipelago in India [26]. These results have been confirmed by
laboratory host preference experiments with Ae. albopictus specimens from La Réunion Island
[57]. This suggests that the feeding behavior of Ae. albopictus may be changing and switching
to humans as a main source of blood, thus increasing the risk of human-to-human transmission
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mediated by this mosquito. (v) Ae. albopictus and Ae. aegypti are sympatric in numerous areas
of the world, often sharing breeding sites and larval habitats [58–61]. This may lead to
competitive interactions between two species eventually leading to the decline of one of the
two. As suggested by field experiments performed in the United States [60, 62] and Brazil [63],
when larvae from Ae. albopictus and Ae. aegypti compete for resources, it is Ae. albopictus that
has a competitive advantage, giving a possible explanation to the local decline and extinction
of indigenous Ae. aegypti populations following the introduction of Ae. albopictus. Altogether,
these data emphasize the potential of Ae. albopictus to substitute Ae. aegypti and become the
main vector of DENV.
2.2. Chikungunya virus
2.2.1. History and epidemiology
The name Chikungunya, meaning “the disease that bends up the joints” comes from the
Makonde people in Tanzania, where the virus was first recognized in 1952 [64, 65]. Although
arthralgia is one of the characteristic symptoms of chikungunya disease, most of the clinical
manifestations are almost indistinguishable from those of Dengue. Thus, it is difficult to trace
back the first epidemics of CHIKV in the literature and historical records. Nonetheless, it is
generally assumed that the virus has been responsible for episodic outbreaks in Africa for
several centuries before being imported to Asia and America by sailing ships during the
eighteenth and nineteenth centuries [66–68].
On the basis of the phylogenetic analysis of the open reading frame of several CHIKV strains,
the virus has been divided into three clades: West African (Waf), Asian, and East/Central/South
African (ECSA), [69]. According to this study, the current CHIKV strains derived from a
common ancestor that existed around 500 years ago. The divergence between the ECSA and
the Asian clades occurred during the end of the nineteenth and the beginning of the twentieth
centuries. Interestingly, despite their close geographic proximity, the ECSA and West African
strains are highly divergent for reasons that are not yet completely understood. The recent
Indian Ocean monophyletic lineage (IOL) originated from the ECSA group at the beginning
of the twentieth century [69].
It is assumed that CHIKV originated in Africa, where it circulated in an enzootic cycle
responsible for sporadic human epidemic outbreaks during the twentieth century in Tanzania
in 1952 [64], Uganda in 1958 [70], South Africa in 1976 [71], Sudan in 1988 [72], and Senegal in
1996 [73], all arising from rural communities in close proximity to forested areas. However,
more recent CHIKV outbreaks linked to indigenous ECSA strains have arisen in urban centers,
as observed in Congo, Cameroon, and Gabon during 2000–2010 [74–76].
In Asia, the virus was first isolated in Thailand in 1958 [77] and was responsible for large
epidemics affecting millions of people in Sri Lanka and India between 1963 and 1973, when
the last CHIKV epidemic was recorded in 2005 [78–80]. This year marks the reemergence of
CHIKV on the Indian subcontinent with the introduction of the IOL coming from islands in
the Indian Ocean [80–82]. Indeed, after its initial detection in Kenya in 2004 [83], IOL subse‐
quently spread to these islands, among which Mauritius, Comoros, Mayotte, Seychelles, La
Réunion, and Madagascar, during 2005–2006 [84, 85]. The extent of the epidemics by this new
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strain is reflected by the example of La Réunion, where 266,000 individuals, a third of the island
population, became infected, which resulted in around 260 deaths, most of them elderly people
[86, 87]. After its introduction in India and Sri Lanka, the IOL CHIKV strains spread quickly
throughout Southeast Asia, being responsible of outbreaks in Malaysia [88], Singapore [89],
and Thailand [90] in 2008, China in 2010 [91], Cambodia in 2011 [92], and Bhutan in 2012 [93].
Overall, it is estimated that CHIKV has caused more than two million cases since 2004 in Africa
and Asia [94]. IOL strains also have become a concern in Europe, where they were imported
by infected travelers returning from India and were responsible for outbreaks in Italy in 2007
[95] and France in 2010 [96] and 2014 [97], both likely transmitted by resident populations of
Ae. albopictus.
In America, the presence of CHIKV has formally been identified in 2013 in Saint Martin Island
during a large and ongoing epidemic in the Caribbean basin [98], although it is suspected to
be responsible for several epidemics since the nineteenth century. Since then, CHIKV has
spread to the other Antilles islands where Ae. aegypti was the only known vector present [98].
The virus then reached Central, South, and North America, where 11 cases of local CHIKV
transmission were recorded in 2014 [9]. Overall, the CHIKV burden in the Americas caused
more than a 1.7 million suspected cases, with almost 60.000 confirmed cases and more than
200 deaths in the 2013–2015 period [99]. Interestingly, this epidemic burden was not initiated
by the highly invasive IOL, but rather by Asian CHIKV strains [98]. These strains have
maintained their endemic circulation in Asia alongside the IOL burden, provoking recent
outbreaks in Indonesia and the Philippines [100, 101] as well as in the Pacific [102].
2.2.2. Transmission and vector competence
Similar to DENV, two modes of transmission have been described for CHIKV that rely on the
same Aedes vectors (Figure 1). In Africa, CHIKV has been circulating in an enzootic cycle
between forest-dwelling Aedes spp. mosquitoes and nonhuman primates as a reservoir [103].
This mode of transmission is believed to be the source of the sporadic and remote African
Chikungunya outbreaks recorded during the twentieth century. However, increasing urban‐
ization and the establishment of anthropophilic and peridomestic Ae. aegypti and Ae. albopic‐
tus populations, seem to be changing the dynamics of CHIKV spread in Africa, provoking
larger epidemics associated with an urban cycle of transmission that relies on humans as a
reservoir. This urban transmission is most likely responsible for the recent Chikungunya
outbreaks in Western Africa [75, 76].
In Asia, CHIKV has traditionally circulated in an urban cycle associated with the presence of
Ae. aegypti and albopictus mosquitoes. As a consequence, Asian CHIKV epidemics have been
larger and have spread more rapidly than those in Africa.
Vector competence studies, (reviewed in [103]), have shown that both Ae. aegypti and Ae.
albopictus are highly susceptible to CHIKV infection and are both able to transmit the virus to
humans. However, the Indian Ocean epidemics have provided a very interesting case of viral
adaptation to a specific vector. Indeed, during the second half of 2005, a genetic change (alanine
to valine substitution) occurred at position 226 of the E1 membrane fusion glycoprotein in the
viral IOL strains that were circulating in the area. This mutation was absent in the initial strains
and became prevalent after its introduction, being present in more than 90% of the isolates
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obtained in La Réunion during 2005–2006 [104]. Further laboratory experiments showed that
this mutation was directly responsible for an increase in CHIKV infectivity for Aedes albopic‐
tus, improving viral dissemination and the transmission to suckling mice without affecting
viral fitness in Ae. aegypti [105, 106]. Interestingly, this mutation was acquired independently
in several distinct geographical locations (India and West Africa) where, similarly to La
Réunion, Aedes albopictus is widely present and is actively displacing indigenous Ae. aegypti
populations. Therefore, it has been suggested that the A226V mutation is a clear example of
convergent evolution, allowing CHIKV viral strains to adapt to the prevalent mosquito vector
[107]. The molecular explanation for the increased fitness in Aedes albopictus conferred by
A226V mutations has not been completely unraveled. It was initially suggested that this
mutation increased the dependency on cholesterol during the virus-host cell fusion step, based
on the observation that mutated CHIKV isolates showed an attenuated viral growth in C6/36
mosquito cells devoid of cholesterol, as compared to original, nonmutated, strains [6, 105].
Therefore, it was suspected that this differential phenotype was responsible for the preferential
replication in Aedes albopictus mosquitoes. However, further studies revealed that there is no
a clear correlation between the dependence on cholesterol and capacity of the virus to infect
Ae. albopictus, suggesting that these are two independent phenotypic effects of the E1 226
mutation [108]. Interestingly, second-step adaptative mutations have been described in A226V
CHIKV strains that further potentiate viral replication in Ae. albopictus. One of these consists
in a leucine for glutamine substitution in position 210 (L210Q) of the E2 protein that mediates
viral binding. This mutation, characterized in viral isolates from Kerala in Southwest India
[109], facilitates infection of midgut epithelial mosquito cells, thereby increasing viral dissem‐
ination and transmission by Aedes albopictus without a significant effect on Ae. aegypti [110].
Altogether, these data demonstrate that some CHIKV strains are rapidly evolving to exploit
Aedes albopictus as a major vector in areas where it is abundant, raising concern about the
epidemic potential of these strains in the Europe and North America where the mosquito is
rapidly spreading.
Another interesting observation is that A226V mutation appeared in ECSA CHIKV strains and
not in the Asian strains circulating in areas where Aedes albopictus is common [111]. This
phenomenon has been attributed to evolutionary constraints imposed by epistatic interactions
between residues 226 and 98 of the E1 glycoprotein. Indeed, all endemic Asian strains have a
threonine in position 98 that is absent in both IOL and ECSA strains and that limits the
adaptative effect of the A226V mutation in Aedes albopictus [111]. This constraint is likely to
guarantee that the ongoing American CHIKV epidemics, caused by Asian strains, will be
sustained by Ae. aegypti instead of Ae. albopictus in areas where they are sympatric [103].
However, this dynamic may change if introduced Ae. albopictus-fitted ECSA and IOL strains
settle in the area.
In addition, a recent experimental study conducted by Stapleford et al. [112] showed the
emergence of two new mutations V80I and 129V on E1 glycoprotein of the CHIKV A226V
strain. Positive selection of these mutations appears to improve the stability and fusogenic
activity of these variants. This study offers an interesting predictive approach to guide the
monitoring of CHIKV strains involved in future outbreaks [112].
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Figure 1. Transmission cycles of DENV and CHIKV. In the sylvatic cycle, primate hosts and several species of Aedes
mosquitoes sustain DENV and CHIKV transmission. Occasionally, rural communities surrounding forests can become
infected. The urban cycle of transmission may have been initiated by the migration of infected individuals from those
rural communities to the cities. The urban cycle involves essentially Ae. aegypti and Aedes albopictus as vectors and hu‐
mans as reservoirs. Adapted from [113–115].
2.3. DENV-CHIKV coinfections
2.3.1. History of reported cases
To date, the number of diagnosed cases of DENV-CHIKV coinfections is surprisingly small
and available information is often incomplete, making it difficult to establish epidemiological
trends. However, it is noteworthy that the number of reported cases has increased considerably
during the past 10 years (Table 1, Figure 2), indicating that the phenomenon is becoming a
concern among the scientific community because of its potential impact on human health and
economy. Indeed, although the first documented cases of DENV-CHIKV coinfections date
back to the 1960s in Vellore, South India, when 14 cases were reported during a CHIKV
epidemic outbreak [116, 117], and in Thailand [118], where nine cases were documented, it
was not until 2006 that the diagnosis of concomitant infections experienced a real interest,
possibly due to the burden of cases of chikungunya infection in the Indian Ocean’s island and
Southeast Asia where DENV is endemic.
In 2006, two cases of coinfection corresponding to two female patients were described in
Malaysia, and 20 more were recorded during the CHIKV outbreak in La Réunion the same
year. More cases of coinfection were reported in Madagascar and Sri Lanka in 2006–2007 and
in Gabon, India, Nigeria and Singapore during 2007–2010, coinciding with the epidemics of
CHIKV caused by IOL strains during this period in the area. The most recent cases were
diagnosed in South America, India and Nigeria in 2013–2014. Of note, two of these cases
corresponded to infected travelers returning to Portugal and Germany after being infected in
Angola and India, respectively [119,120], raising concern about the possible spread of coin‐
fection cases in Europe where Aedes albopictus is present.













NSa NS NS NS [118]
14 Vellore, India 1964 DENV-2 NS Absence NS [116, 117]
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2006 DENV-1 X 1 case of DHF NS [122]
10 Toamasina,
Madagascar


















2008 NS NS Absence NS [119]
63 Nigeria 2008 NS Absence NS [126]




X 2 DHF, 1 dead NS [127]







X 3 cases of DHF NS [129]





X Absence Ae. aegypti [130]
1 Nigeria 2014 NS NS Absence NS [131]
1 Luanda,
Angola
2014 DENV-4 X Absence NS [120]
2 India NS NS NS Absence NS [132]
Table 1. Reported cases of DENV/CHIKV coinfections. a NS: Not specified.
As shown in Table 1, the four serotypes of DENV can be found in association with both the
Asian and ECSA CHIKV clades, depending of the strain of CHIKV that cocirculates with
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DENV in a particular area, pertaining to Asian CHIKV strains in America and ECSA strains
in Asia and Africa. However, it would be interesting to study if some particular associations
of DENV and CHIKV genotypes are favored in nature. For example, is the circulation of some
virulent DENV strains associated with the simultaneous presence of specific CHIKV geno‐
types? Such preferential associations could provide insight into viral coevolution and allow to
define strategies to limit the morbidity associated with certain highly pathogenic viral strains.
2.3.2. Transmission and vector competence
Some of the studies reported in Table 1 provide interesting information about the relative
importance of Aedes albopictus and Ae. aegypti in the spread of coinfection cases in natural
conditions. Perhaps the most complete and documented cases of coinfection from an epide‐
miological perspective have been provided by a large clinical, virological, and entomological
study performed in Gabon between 2007 and 2010 [124, 125]. During this period, an active
surveillance of acute febrile symptoms was implemented in the healthcare centers of Libreville
and all the major towns of the country. Blood was sampled from patients who met the case
definition for diagnosis of CHIKV and DENV infection, as determined by quantitative PCR
[124, 125]. A total of 4287 patients were tested among which 1567 (36.6% of the individuals)
were CHIKV-positive, 376 (8.3%) were DENV-2 positive (no other serotype was reported) and
37 (0.9%) were coinfected with both viruses. All cases occurred in densely populated areas
during the rainy season, when conditions are ideal for mosquito breeding. Two large epidemic
outbreaks were observed, during 2007 and 2010, with sporadic cases in between. In 2007, the
vast majority of CHIKV and DENV-2 infections were reported around the capital Libreville,
in the Northwest, with nine cases of coinfection. During 2008 and 2009, the viruses moved to
Lambaréné, Ndjolé, and Lastourville in the center and the south of the country, respectively,
however no cases of coinfection were reported. Finally, the 2010 outbreak occurred in the
southeast of the country and was centered around Franceville, close to the Congo border where
28 cases of coinfected patients were recorded. The phylogenetic study, based on the isolates
recovered from monoinfected and coinfected patients not only showed that CHIKV belonged
to the ECSA lineage, but also that the Gabonese strains from 2010 derived from those reported
in 2007, which were in turn closely related to the CHIKV strains isolated in 2006 from an
outbreak in Cameroon [74]. These findings suggest that CHIKV is spreading rapidly in
Western Central Africa with a north to south dynamic, a trend that seems to be confirmed by
the identification of the virus in Southern Congo in 2011 [133] and Angola in 2014 [120]. On
the other hand, DENV-2 isolates from 2010 also derived from those of 2007 and were found to
cluster in the cosmopolitan genotype, which gathers strains isolated in diverse areas of the
world such as India, China, Australia, and Saudi Arabia. The most likely explanation for these
observations is that the DENV-2 Gabonese strains were imported by infected travelers coming
from the latter areas or by infected mosquitoes introduced in Gabon along with imported
products [124, 125].
During this study, mosquitoes were captured around the coinfected patient’s homes. After
identification of the species, viral presence was determined by quantitative PCR from pooled
mosquitoes abdomen. In total, 661 Aedes mosquitoes were analyzed. A large majority of the
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mosquitoes was constituted by Ae. albopictus (571 specimens, 86% of the caught specimens),
followed by Ae. simpsoni and Ae. aegypti (52 and 38 specimens, respectively). From the 46 pooled
abdomens of Ae. albopictus 11 (23.9% of total) tested positive for CHIKV, 18 (39.1%) for DENV-2
and three (6.5%) for both viruses. This was the first report of a concomitant infection of
mosquitoes by CHIKV and DENV in nature. In the case of Ae. aegypti, one out of the three pools
(33.3%) tested positive for CHIKV, whereas DENV-2 was not detected. All three Ae. simpsoni
pools tested negative for both viruses. Although the lack of detection of both viruses in Ae.
aegypti specimens could be attributed to the large predominance of Ae. albopictus, which
increases the probability of the latter vector to be coinfected, another study comparing the roles
of the two species in the emergence of DENV and CHIKV in central Africa confirmed that the
only species naturally infected by DENV and CHIKV was Ae. albopictus [135]. This is not
surprising with respect to CHIKV, because the viral isolates circulating in the area have
acquired the A226V substitution and are therefore particularly adapted to grow in Ae.
albopictus [107, 125]. The absence of Ae. aegypti, naturally infected with DENV, has been
attributed to the poor susceptibility of this mosquito to DENV in this region, explaining the
lack of DENV outbreaks in West and Central Africa until the turn of the century with the
introduction of Ae. albopictus [39]. This notion has been confirmed by laboratory experiments
showing that Ae. aegypti specimens collected from Cameroon are less susceptible to DENV
infection than mosquitoes of Asia and South America [135].
Besides its greater susceptibility to CHIKV and DENV, Ae. albopictus may be more efficient in
the maintenance of DENV and CHIKV transmission cycles because of its aggressive feeding
behavior, with a human biting rate that is significantly higher than the one observed in Ae.
aegypti populations in suburban areas of Central Africa, according to a study led by Paupy et
Figure 2. Geographical distribution of Aedes albopictus and Aedes aegypti populations and locations where DENV/
CHIKV coinfections have been described. Adapted from [134].
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al. [135]. This may increase the probability of Ae. albopictus mosquitoes of becoming infected
by DENV and CHIKV and transmitting the viruses to human hosts.
These data indicate that Ae. albopictus is more fitted to transmit both viruses and to act as the
primary vector of DENV and CHIKV in Gabon which should raise concerns about the spread
of CHIKV/DENV coinfections to the rest of Africa in view of the continuing progression of Ae.
albopictus on this continent.
The disproportion in the abundance of Aedes species in Gabon is striking as Ae. albopictus was
first reported in the country in 2006 [136, 137], suggesting that the species is rapidly prolifer‐
ating and actively displacing endemic populations of Ae. aegypti. This trend has been confirmed
by a subsequent entomological study carried in different locations of Gabon, demonstrating
that Ae. albopictus largely outnumbered the endemic Ae. aegypti populations in suburban areas
where patches of vegetation are likely to be present, as well as in small towns particularly
affected by the 2007–2010 DENV/CHIKV epidemics such as Cocobeach, Oyem, and Lastour‐
ville [135].
This trend and the role of Ae. albopictus as the main vector of CHIKV/DENV coinfections were
confirmed by Ratsitorahina et al. who conducted a virologic and entomologic study in the city
of Toamasina, located in the eastern coast of Madagascar, following an outbreak of dengue-
like symptoms (DLS) [123]. CHIKV was suspected as the etiologic agent, because the virus was
previously detected in La Réunion, the Seychelles, and Comoros archipelagos during the IOL
CHIKV epidemic. Blood samples were taken from 55 febrile patients manifesting headache,
myalgia, arthralgia, retroorbital pain, or rash. Molecular and serological diagnostics identified
CHIKV (IO lineage, highly adapted to Ae. albopictus) and DENV-1 (closely related to strains
isolated in La Réunion in 2004) in 38 of the 55 patients, among which 10 cases corresponded
to coinfections. An entomologic study was performed in five neighborhoods in which DLS
were reported, by catching mosquitoes larvae and adults in potential breeding sites. Ae.
albopictus, a species that has been circulating in Madagascar since the 1970s [58], was the only
urban vector of DENV and CHIKV and no other species were identified. Among all the
mosquito pools tested for the presence of CHIKV and DENV, 21.7% tested positive for CHIKV.
Data for DENV was not given. The identification of the breeding sites revealed that populations
of Ae. albopictus from Toamasina exploit diverse artificial peridomestic containers such as tires,
coconut shells, discarded cans, pots, etc., which are traditionally associated with Ae. aegypti
populations. This highlights the notion that Ae. albopictus is able to adapt to the ecological
niches found in urban areas and therefore could replace Ae. aegypti as the main vector of the
urban transmission cycle of DENV and CHIKV. Accordingly, a large entomologic survey
carried in 15 sites across Madagascar during the 2007–2009 period, revealed that Ae. albopic‐
tus has extended its geographical distribution on the island and that its population density has
become consequently higher than that of Ae. aegypti, a species that is becoming rare. This
contrasting result to what was previously reported in the 1970s–1980s, can be explained by the
environmental plasticity of this species that exhibits a greater capacity to adapt to different
climatic conditions and to anthropogenic changes in the natural habitats, as compared to Ae.
aegypti [58].
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Vector competence studies performed in laboratory conditions have shown that Ae. albopic‐
tus specimens from La Réunion are able to disseminate DENV and CHIKV and to deliver both
infectious particles concomitantly in its saliva after being orally exposed to DENV and CHIKV
strains, circulating in the island during 2004–2006 [138]. Another study revealed that Ae.
aegypti, orally fed with CHIKV and DENV, is unable to sustain dual infection [139]. Although
these results should be interpreted with caution since vector susceptibility is highly dependent
on the origin of Aedes specimens, as well as the type of CHIKV and DENV strains involved in
the infection, they corroborate what has already been shown in natural conditions and
furthermore confirm the potential of Ae. albopictus to transmit both viruses more efficiently
than Ae. aegypti.
Taken together, these results reveal an important and threatening role of Ae. albopictus through
its ability to concomitantly transmit DENV and CHIKV in areas where it circulates sympatri‐
cally with Ae. aegypti. It is to be noted however, that in locations where Ae. albopictus is still
absent, Ae. aegypti can sustain the concomitant transmission of both viruses, as recently
reported during the Caribbean CHIKV outbreak. This epidemic that initiated in Saint Martin
then spread to the French Antilles, causing a total 570 confirmed cases of infection with the
Asian strain of CHIKV, 65 with DENV and 16 cases of coinfection (Table 1) [130]. Ae. aegypti
was identified as the unique potential vector of this outbreak [98]. Nonetheless, because of the
rapid propagation of Ae. albopictus in South America, this dynamic may change in a close
future.
Another important topic related to CHIKV/DENV coinfections, is the mode by which these
viruses can be transmitted to humans. Two main possibilities could be envisaged: an individ‐
ual transmission of each virus by different monoinfected mosquitoes or concomitant trans‐
mission by a coinfected vector. In that sense, the study performed by Caron et al. [124] gives
several interesting clues based on the analysis of viral loads detected in coinfected Gabonese
patients. The results revealed the presence of two distinctive groups of patients, based on the
presence of viral RNA-derived complementary DNA (cDNA): one group with a high DENV-2
cDNA load and low CHIKV cDNA load and the other with high cDNA levels of both viruses.
According to this pattern of infection, the authors suggested two different modes of transmis‐
sion. In patients with the highest DENV-2 cDNA, the blood samples were most likely taken
during the acute phase of DENV infection and the early or late stage of CHIKV infection,
suggesting that the viruses were more likely to have been transmitted by the bite of two
different mosquitoes each infected with one virus, although with several days of interval,
which might explain the gap between the replication kinetics of either virus. However this
interpretation should be taken with caution, as several other possibilities may exist. For
example, both viruses could have been transmitted by the same mosquito and DENV-2 might
have replicated more efficiently than CHIKV due to genetic factors intrinsic to the human host,
thus establishing a competitive state in which CHIKV could have been disadvantaged.
Alternatively, DENV-2 viral load in the coinfected mosquito salivary glands may have largely
exceeded that of CHIKV. As a result, the number of DENV viral particles transmitted to the
human host during the mosquito bite may have been higher than for CHIKV, consequently
explaining the difference in the observed cDNA loads. Another possibility, noted by Caron et
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al. [124], is that the immune response against DENV may have limited the replication of
CHIKV. In the second group of patients with high cDNA loads for both viruses, indicative of
a blood sample taken during the acute phase of both CHIKV and DENV-2 infections, the dual
infection may have resulted from two rapidly succeeding bites of different mosquitoes, each
infected by one virus or from the bite of a single coinfected mosquito [124].
3. Pathogenesis
From a public health perspective, the concern about coinfections is their possible impact on
the pathogenesis and the outcome of dengue and chikungunya diseases. Is there a correlation
between the cases of coinfection and the severity of symptoms? Because, in terms of morbidity,
severity and mortality DENV has a higher impact on human health than CHIKV, the major
preoccupation is that CHIKV/DENV coinfection could increase the incidence of DHF and DSS.
DHF symptoms appear around the time of defervescence, 3–7 days after the first symptoms
of DF. It is characterized by an increase in capillary permeability with a loss of plasma volume
that is preceded by thrombocytopenia and leukopenia. Hamorrhagic symptoms include
petechiae, ecchymoses, and purpuric lesions. If a critical volume of plasma is lost through
leakage, DSS may follow. This phase is characterized by a narrow pulse pressure that can be
underestimated as most of the patients remain conscious and lucid. Prolonged hypotensive
shock and hypoxia may result in organ failure, acidosis, intravascular coagulation, and death
if not corrected in time [3, 4].
Although the pathogenesis of DENV infection is not well understood, several risk factors may
increase the severity of the disease: the viral genotype (the Asian genotype of DENV-2 is
considered to be a virulent strain), the age (children are less able to compensate plasma leakage
than adults), the ethnicity (Caucasian are more susceptible to develop severe forms of the
disease), chronic diseases (individuals with allergies, asthma, and diabetes are at higher risk
than healthy people) and secondary infection with a new DENV serotype [140–143]. The latter
issue has received particular attention, because it may be a major determinant for the devel‐
opment of severe cases of dengue. Indeed, when preexisting antibodies from a primary DENV
infection bind to an infecting DENV particle during a subsequent infection with a different
dengue serotype, the antibodies from the primary infection cannot neutralize the virus.
Instead, the resulting antibody-virus complexes attach to Fc receptors at the surface of
monocytes, macrophages, and dendritic cells (DCs), resulting in increased infection [113, 144,
145]. This phenomenon, known as antibody-dependent enhancement of infection (ADE), may
explain the higher viremia and levels of circulating antigens detected in patients with DHF as
compared to patients with DF [146, 147]. ADE accounts for the particular propensity of
populations living in DENV hyperendemic regions to develop severe forms of dengue. ADE
may also contribute to increased capillary permeability and to a “cytokine storm” that could
aggravate the disease [148–150]. Another phenomenon increasing the risk of severe disease
during secondary infections with DENV is the original antigenic sin or Hoskins effect. This
effect refers to the tendency of the immune system to respond to a secondary infection through
Dengue and Chikungunya Coinfection – The Emergence of an Underestimated Threat
http://dx.doi.org/10.5772/64426
81
the activation of memory B and T cells induced by the primary infection. These cells show a
decreased affinity for secondary antigens and are less effective in the control of the infection
[151]. In particular, it has been shown that during the secondary infection by a different strain
of dengue virus, the cytotoxic T lymphocytes release cytokines, rather than causing the lysis
of infected cells, thereby increasing vascular permeability and exacerbating the damage of
endothelial cells [152]. Taken together these data indicate that secondary heterotypic infections
with DENV are an important factor in the aggravation of dengue disease.
However, despite the identification of risk factors, little attention has been paid to the potential
effect of the simultaneous presence of CHIKV on the propensity to develop DHF. To date, the
scarcely available clinical data about coinfections impedes to establish clear conclusions. The
large majority of the studies analyzing the clinical symptoms of CHIKV/DENV coinfected
patients failed to identify a particular predisposition to develop DHF, as no severe symptoms
were observed (Table 1). Furthermore, two studies that compared the biological and clinical
symptoms between monoinfected and coinfected patients did not observe more severe
manifestations or biological disorders in patients with a mixed infection, suggesting that the
two viruses do not exert additive effects [124, 153].
The rare cases of DHF in coinfected patients were observed in one of the two patients coinfect‐
ed in Malaysia [122] and in India in 2009 [127]. The latter case deserves further attention: during
this episode of DENV/CHIKV coinfections in Delhi, 69 blood samples were taken from patients
with acute fever. Forty-eight were DENV-positive, eleven tested positive for ECSA lineage and
six were positive for both viruses. From these six samples, three were positive for DENV-3, one
for DENV-4, one for DENV-3/DENV-4 and one for DENV-1/DENV-4, constituting the first cases
of concomitant infections with multiple DENV serotypes in CHIKV/DENV infected patients.
Two of the six patients manifested severe hamorrhagic symptoms with central nervous system
involvement and one died. It was not specified whether the severe cases corresponded to patients
infected with a single DENV serotype or with two different serotypes, making it difficult to link
the severity of the disease to the concomitant presence of CHIKV or to the presence of two
different  DENV  serotypes.  However,  the  particular  high  incidence  of  severe  symptoms
following superinfection by CHIKV and several DENV serotypes highlights the potential threat
of CHIKV infection to human health in areas where DENV is hyperendemic [127].
Overall, these results do not establish a clear association between the severity of dengue and
chikungunya diseases and the concomitant presence of both viruses. However, the number of
CHIKV/DENV coinfections reported to the date is too small to draw firm conclusions. Further
studies need to be undertaken with large cohorts of infected patients to gain better insight in
this process, particularly taking into account that many severe cases associated with coinfec‐
tions may have passed unnoticed, as the diagnosis of both viruses has not systematically been
undertaken in the past. Moreover, the increase in coinfections with both viruses could lead to
a rapid viral evolution, potentially resulting in the appearance of highly infective and patho‐
genic CHIKV and DENV strains.
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4. Cell biology of CHIKV/DENV coinfections
Very little is known about the interactions that are established by the viruses and their host
cells during coinfections. The fact that viral RNA of both viruses has been detected in Aedes
abdomens strongly suggests that they can disseminate and coexist simultaneously in these
mosquitoes. Accordingly, both viruses are able to concomitantly infect Ae. aegypti midgut and
upregulate the expression of proteins involved in the oxidative stress, energy production, and
carbohydrate/lipid metabolism. This shows that CHIKV and DENV are able to simultaneously
circumvent the physical barrier established by the midgut to propagate to other Aedes organs
and tissues [154]. However, almost nothing has been described at the cellular level: to date,
only one work addressed the concomitant effect of CHIKV/DENV infection in mosquito cells
but no information is able regarding vertebrate cells.
In this study, Potiwat et al. [155] infected Ae. albopictus C6/36 cells with different multiplicities
of infection (MOIs) of CHIKV (ECSA strain) and DENV-3 isolates from Southern Thailand,
detecting the presence of viral RNA in cell culture medium by RT-PCR. They observed that
both viruses were able to replicate and generate viral progeny when cells were challenged
simultaneously with a mixed viral preparation in which the viruses were added at the same
MOI. However, when the proportion of viral input was changed and the titer of DENV largely
exceeded the one of CHIKV, DENV was able to suppress CHIKV replication. The reciprocal
(larger titer of CHIKV than DENV) did not exert any effect on DENV replication. When
infection by each virus was performed sequentially at the same titer (superinfection conditions
in which one virus was added 1 hour before the other), viral progeny was detected for the two
viruses independently of the order of infection. Although these experiments were not vali‐
dated with other viral strains and mosquito cells, they provide the first cell biology evidence
that both viruses can replicate actively in the same cells when these are challenged simulta‐
neously or sequentially. This supports the two modes of mosquito coinfection that have been
suggested to occur in natural conditions: a mosquito could get coinfected by ingesting its blood
meal from a viremic individual carrying both viruses, or sequentially by ingesting the blood
from two different individuals each infected by a single virus. When the blood meal is taken
from a single individual, the successful replication of both viruses in mosquitoes may require
some conditions to be fulfilled, such as the presence of enough infectious CHIKV/DENV
particles in a proportion that falls within a certain range. In other words, the quantity of one
of the viral species should not overwhelmingly exceed the other one to avoid any competitive
suppression. In that sense, a very recent study performed by Nuckols et al. [156] seems to
confirm in vivo what is observed at the cellular level. In this work, Ae. aegypti and Ae. albopic‐
tus mosquitoes were challenged either simultaneously or sequentially with CHIKV and
DENV-2 mixed in blood meals. After mosquito sacrifice, viral dissemination and transmission
potential were assessed by detecting CHIKV and DENV RNA in the mosquito’s head and
saliva, respectively. The results show that both Aedes species exhibited a dual disseminated
infection when viruses were administered at the same time or sequentially. However, CHIKV
and DENV were only detected concomitantly in mosquito’s saliva from specimens exposed to
each virus sequentially and not simultaneously. Thus, this laboratory experiments suggest that
Aedes mosquitoes are able to transmit both viruses to vertebrate hosts when they acquire
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CHIKV and DENV with a time interval and that simultaneous acquisition of both viruses may
generate competitive interactions that decrease their potential transmission. Although in this
study the viral titers of DENV (3.2 × 106 focus forming units/mL) and CHIKV (1.5 × 105 plaque
forming units) used to infect the mosquitoes were not comparable, it would have been
interesting to assess if the competitive exclusion was due to the excess of one viral species over
the other one or if it could be seen independently of the viral input.
In the work of Potiwat et al. [155], competitive suppression was only observed when the
amount of viral particles from DENV largely exceeded the one from CHIKV and not the
reciprocal. Both viruses are able to exploit similar cell surface receptors for attachment, such
as prohibitin and heat shock proteins that can be found in mosquito cells [157–160], leading to
possible competitive interactions between both viruses for attachment and viral entry.
However, it is highly unlikely that this is the reason for the suppression of CHIKV replication
by DENV, as no inhibition of DENV replication was observed when CHIKV particles out‐
numbered DENV particles, as it would be expected if the viruses rely on the same receptors
for infectious entry. An alternative, is that the viruses are able to exploit different receptors on
the same cell, and that an excess in DENV particles attached to the cell surface sterically
interfere with CHIKV-receptors interactions. Another possibility is that the excessive entry of
infectious DENV particles leads to the hijacking of cellular components necessary for CHIKV
replication, or to the production of viral components that inhibit CHIKV infection.
There is no information about the cellular biology of CHIKV/DENV coinfection in mamma‐
lian  cells  and  we  can  only  speculate  about  the  possible  mechanisms  involved  in  viral
replication. As summarized in Table 2, CHIKV and DENV share similar mechanisms of entry,
which  could  lead  to  suppressive  competition  between  the  viruses  in  the  early  steps  of
infection. For example, they are able to exploit similar cellular receptors for attachment, they
are  internalized mainly  by clathrin-mediated endocytosis  and their  fusion occurs  in  the
endosomal system. The cellular tropism is also similar, although it seems to be larger in the
case of DENV, a phenomenon that could be explained by the longer and more frequent
circulation of the virus among human beings, allowing it to adapt and exploit a more diverse
range of cellular targets. However, the viral RNA of both viruses can be detected in the blood
of coinfected humans, suggesting that they are both able to concomitantly invade, replicate
and spread in different organs to establish a systemic infection resulting in viremia. Thus,
these viruses seem to have adopted different replicative strategies to overcome the poten‐
tial competition for cellular resources when they infect the same mammalian cells, and/or
have established cooperative interactions to guarantee their  survival  and propagation in
human hosts. For example, during the cellular attachment step, the viruses may use different
not yet characterized receptors or use an abundant cell surface molecule to limit competi‐
tion. Also, although both viruses enter cells by clathrin-mediated endocytosis, some differen‐
ces exist in the pathways and molecular partners involved in the process between CHIKV
and DENV. Indeed, the depletion of the fuzzy homologue (FUZ),  a cytoplasmic effector
protein involved in planar cell polarity, ciliogenesis, and mammalian embryonic develop‐
ment,  strongly  inhibits  clathrin-mediated  endocytosis  of  CHIKV and other  alphaviruses
without affecting DENV entry [161].  This suggests that both viruses exploit  parallel  cla‐
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thrin  pathways  involving  different  effector  proteins.  Furthermore,  DENV  and  CHIKV
membrane fusion, a step necessary for the release of the viral genome in the cell, takes place
in distinct cellular compartments: the first one occurs in Rab7+ late endosomes, while the
second one takes place preferentially in Rab5+ early endosomes [162–164].The explanation
for the selective use of these compartments could be linked to the lipidic composition of the
endosomes: fusion of flaviviruses seems to require the presence of anionic lipids such as
phosphatidylserine and bis(monoacylglycero)phosphate that are present in the late endo‐
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Table 2. Comparison of CHIKV and DENV tropism’s in humans and of the replicative strategies developed by these
viruses in mammalian cells.
Also, fusion of alphaviruses seems to depend on the activity of the TSPAN9 tetraspanin
protein, as depletion of the protein selectively blocks the fusion of Semliki Forest Virus (SFV)
without altering the one of DENV. TSPAN9 may control the correct routing of the viruses to
the early endosomes and maintain these compartments in a permissive state for alphaviruses
fusion but not for flaviviruses [161].
There are also differences in the mechanisms involved in CHIKV and DENV synthesis of viral
proteins, genome replication and assembly of the viral components to form mature infectious
virions (Table 2). In the case of CHIKV, almost all the information about these processes has
been inferred from studies performed with related alphaviruses such as SFV and Sindbis Virus
(SINV). Once the viral genome is released into the cytoplasm, it is translated from two different
open reading frames to generate the nonstructural (nsP1234) and structural (C-pE2-6K-E1)
polyproteins [5, 180]. The nonstructural polyprotein is cleaved by the nsP2 viral protease to
generate the individual nonstructural proteins that are going to form replication complexes
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(RCs) in charge of the viral genome replication [195]. These RCs are associated to virus-induced
membranous cytoplasmic structures that are derived from the endosomes and lysosomes [181–
184]. The structural polyprotein is cleaved autoproteolitically by the C protein which is
released in the cytoplasm. The rest of the polyprotein (pE2-6K-E1) is translocated to the
endoplasmic reticulum (ER) where it is further processed by the host cell signal peptidase to
generate the individual PE2, 6K, and E1 proteins [196]. These proteins are then routed to the
plasma membrane through the Golgi network where the furin-like protease cleaves the pE2
to generate the E2 and E3 mature proteins. At the plasma membrane, all the structural proteins
gather together along with the genomic viral RNA, and the interaction between the C and E2
proteins drives the budding process, giving rise to enveloped virions that are released to
external medium [191, 192].
In the case of flaviviruses, upon release of the viral genome into the cytoplasm, the nonstruc‐
tural (NS) and structural proteins are translated from a single ORF to generate a large poly‐
protein that translocates to the membrane of the ER. There, the viral NS2B-NS3 protease and
the host cell signalase cleave the polyprotein to generate the individual nonstructural proteins
and the C, pre-Membrane (prM) and E proteins [185–188]. The nonstructural proteins form
RCs associated to virus-induced membranes derived from the ER, known as vesicle packets,
and drive the replication of the viral genome [189, 190]. Flavivirus assembly results from the
association of C proteins with the genomic RNA into ER-derived membranes where all the
structural proteins are displayed. The assembly generates immature viral particles that acquire
their lipid envelope by budding into the lumen of the ER. These particles are routed through
the Golgi network, and final maturation occurs at the trans-Golgi where the furin cleaves the
prM to generate the mature M protein. These mature virions are then secreted to the external
medium [193, 194].
Thus, the different replicative strategies, assembly compartments and release mechanisms
used by flaviviruses and alphaviruses, may allow CHIKV and DENV to replicate simultane‐
ously without a substantial overlap in their cellular requirements.
Another tempting possibility is that both viruses contribute to shut-off the antiviral cellular
mechanisms, creating a favorable environment for viral replication. For example, the type I
interferon response (IFN I) represents an important antiviral response against DENV and
CHIKV. Accordingly, treatment with either IFN-α or IFN-β suppresses the replication of both
viruses in cell culture [170, 197, 198]. Therefore, CHIKV and DENV have developed strategies
to counteract the cellular defense system. In the case of DENV, almost all the nonstructural
proteins are able to alter the IFN I response. Indeed, NS2A and NS4B inhibit the interferon α/
β response by blocking the activation and translocation of the signal transducer and activator
of transcription 1 (STAT1) to the nucleus and the subsequent transcription of antiviral genes
[199]. Furthermore, DENV NS2B/NS3 proteolytic activity has been involved in the inhibition
of type I IFN response by degrading human stimulator of interferon gene (STING) protein in
dendritic cells, which are known to be a primary target of DENV [200, 201]. STING is an adaptor
protein that senses nucleic acids of incoming pathogens and triggers signaling pathways that
activate the expression of IFN I and proinflammatory cytokines [202, 203]. DENV NS5 protein
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is also able to interact with STAT2 and bridge the protein to cellular ubiquitin ligases, thereby
promoting the STAT2 proteasome-dependent degradation [204, 205].
In the case of CHIKV, it has been established that nsP2 is a potent inhibitor of the type I and
II IFN-stimulated JAK-STAT signaling by blocking the phosphorylation of STAT-1 and its
translocation to the nucleus [206]. Therefore, a scenario could be envisioned in which the IFN
response inhibitory effects of CHIKV and DENV nonstructural proteins are added to create a
more potent shut-off of the antiviral cellular response that would be beneficial for both viruses.
5. Perspectives and challenges
Very little is known about the ecology and biology of CHIKV and DENV coinfections. Since a
decade, the increasing number of reported cases in Asia, Africa, and America shows that it is
a generalized phenomenon that has been underestimated. Both Ae. aegypti and Ae. albopictus
mosquito vectors are able to transmit these viruses and have been directly involved in some
of the coinfection cases described to the date. A particular attention has been paid to Ae.
albopictus, as: (i) it is the only species that has been shown to sustain concomitant infection by
both viruses in natural conditions: (ii) it is an aggressive species that is spreading worldwide
and displacing resident populations of Ae. aegypti; (iii) it is installed in the northern hemisphere
contrary to its Ae. aegypti counterpart, representing a threat for the transmission of CHIKV and
DENV among nonimmune populations in Europe and North America. However, further
studies are required to evaluate the precise impact of each Aedes species on the transmission
of DENV and CHIKV taking into account that infection susceptibility, vector ecology and
interactions among sympatric populations of Aedes mosquitoes can deeply vary between
geographical regions. A better understanding of these dynamics at the local level may allow
to adapt vector control measures to each situation according to the results obtained from the
field.
The clinical consequences of CHIKV/DENV coinfections remain largely unknown. Indeed, the
available data is not enough to conclude if the concomitant infection by both viruses is able to
aggravate the clinical symptoms caused by DENV and CHIKV monoinfections. A systematic
and larger clinical survey should be done to assess if coinfections are associated to severe forms
of dengue and chikungunya diseases. This is particularly important, as clinical studies may
justify further research on the pathogenesis of CHIKV/DENV coinfections to understand the
immunological events that are triggered. This information could be useful to design and
improve prophylactic vaccines against each virus.
Finally, the almost complete absence of information on the cell biology of CHIKV and DENV
coinfections open a large range of research opportunities. In that sense, the mechanisms by
which the viruses avoid competition or find cooperative mechanisms to replicate simultane‐
ously are two major axes of research that should be addressed more deeply. By identifying
common cellular targets of both viruses, antiviral drugs may be designed to treat coinfected
patients or even to produce vaccines that are able to concomitantly immunize against both
viruses.
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